18f-ftc-146
Small moleculeexperimentalImaging agent
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02753101)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Chronic Pain · Phase 1
- Complex Regional Pain Syndromes · Early Phase 1
- Fasting · Phase 1
- Fragile X Syndrome · Phase 1
- Healthy Volunteers · Phase 1
- Intermittent Claudication · Phase 1
- Neuralgia · Phase 1
- Nociceptive Pain · Phase 1
- Pain · Phase 1
- Radiculopathy · Phase 1
- Sciatica · Early Phase 1
- Spinal Cord Diseases · Phase 1
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- 18f-ftc-146
- 18f-ftc-146
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06599151 | Phase 1 | Oct 1, 2024 | Stanford University |
| NCT04435821 | Phase 1 | Aug 31, 2020 | General Electric, Stanford University |
| NCT04314856 | Phase 1 | Jun 30, 2020 | Stanford University |
| NCT03649555 | Phase 1 | Oct 1, 2018 | Stanford University |
| NCT03556137 | Phase 1 | Jun 30, 2018 | General Electric, Stanford University |
| NCT02753101 | Early Phase 1 (Phase 1) | Feb 1, 2016 | Stanford University, University of Mississippi |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Stanford University | Academic/Hospital | 6 | 6 | 1 | 2016 |
| General Electric | For profit | 2 | 0 | 1 | 2018 |
| University of Mississippi | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1